Patients with AD also experience altered circadian rhythm, incontinence, eating pattern, wandering, and aggression. (Lovestone, 2009; Richards and Sweet, 2009 ).
The Relationship between Neuropathology and Cognitive and Behavioural Features of Alzheimer's
Disease 4.1. Neurotransmitters 4.1.1 Acetylcholine Francis et al (1999) , Sarter and Parikh (2005) have reviewed, at first, the studies of atropine and scopolamine which showed they impaired cognitive abilities in animals and humans, thus cholinergic system had an important role in cognitive functions. In another review by Tampi et al (2011) , the cholinergic systems have experienced pathological state which cause Behavioural and Psychological Symptoms of Dementia (BPSD) over denervation of temporal and frontal cortices, and as Minger et al (2000) , cited by Garcia-Alloza et al (2005) have written, BPSD may be linked with the absence of choline. Garcia-Alloza et al (2005) have also found, aggressive behaviour have been related to low levels of cholineacetyltransferase (ChAT) and acetylcholinesterase (AChE). Almost a decade ago, there was a consensus that cholinergic augmentation was effective in developing memory, concentration, attention, and psychiatric symptoms of AD, discreetly. (Grabowski and Damasio, 2004) . Until now, many drug studies have been done in relation with the cholinergic neurons in AD. Tampi et al (2011) have reviewed, auditory and visual hallucinations were associated with serotonin receptor polymorphism, and the presence of visual hallucination was associated with Ser23 allele. It was concluded that psychosis and behaviour phenotype were associated with the serotonin transporter promoter region (5-HTTPR) I allele. In another study by Garcia-Alloza (2005), they found that overactivity was associated with 5-hydroxytryptamine (5-HT) levels in Brodmann area 10 (frontal cortex), and psychosis was associated with 5-HT levels in Brodmann area 20 (temporal cortex). They also found women with AD experienced delusions higher than men, in relation with the ratio of 5-HT/ AChE in temporal cortex.
Serotonin

Dopamine
It has been thought that symptoms of aggression and psychosis in white subjects with AD have been related with dopamine receptor genes DRD1 B2/ B2 homozygotes, and the carriers have been more likely to experience hallucination and be aggressive. Psychosis has been related with the DRD3 1/ 1 or 2/ 2 homozygotes, and DRD3 polymorphism. Delusions have been experienced by the carriers of DRD3 1 allele. (Sweet et al., 1998; Holmes et al., 2001) .
Amyloid β Protein (Aβ Protein)
Recently, it is known that the cognitive disturbance in patients with AD is because of widespread synapses loss in cortical regions. The cause of synaptotoxicity in AD is the self-aggregation of Aβ into soluble low-n oligomers. Animal and postmortem studies have complemented in vitro studies that has shown on synapses the deleterious effect of Aβ oligomers. In human studies, soluble Aβ associated with synapse loss and cognitive impairment, in the early event of AD. (Richards and Sweet, 2009 ). Another evidence shows that mutations in amyloid precursor protein (APP), resulting from unindirectional cascade, has risen to neurofibrillary tangle and plaque formation, whilst in tauopathies, although mutation in tau gene has risen tangle formation, there is not plaque formation. (Lovestone, 2009 ).
Apolipoprotein ε (APOE)
Apolipoprotein ε4 allele gene (APOE4) is related with the late-onset AD. The risk of people who carry APOE4 in familial or sporadic cases are higher than people who do not carry it. Two-to fourfold increased risk have been found for people who have a copy of APOE4, and four-to eightfold increased risk for people who have two copies of it. (Richards and Sweet, 2009 ). Tampi et al (2011) have reviewed that in patients with AD: 1) The 3/ 4 genotype of APOE4 caused higher rates of psychosis and depression when compared to control, 2) Significantly lower epsilon 2 allele of APOE in the depressive group when compared to control and it caused symptoms of depression in late-onset AD.
